UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Two-stage phase II oncology designs using short-term endpoints for early stopping

Statistical methods in medical research, 2017-08, Vol.26 (4), p.1671-1683

2017

Volltextzugriff (PDF)

Case management for patients with chronic systolic heart failure in primary care: the HICMan exploratory randomised controlled trial

Trials, 2010-05, Vol.11 (1), p.56-56, Article 56

2010

Volltextzugriff (PDF)

Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations

Biometrical journal, 2017-03, Vol.59 (2), p.344-357

2017

Volltextzugriff (PDF)

Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints

Statistical methods in medical research, 2023-09, Vol.32 (9), p.1749-1765

2023

Volltextzugriff (PDF)

Patient- and provider-related determinants of generic and specific health-related quality of life of patients with chronic systolic heart failure in primary care: a cross-sectional study

Health and quality of life outcomes, 2010-09, Vol.8 (1), p.98-98

2010

Volltextzugriff (PDF)

Strategies for Reducing Potentially Avoidable Hospitalizations for Ambulatory Care–Sensitive Conditions

Annals of family medicine, 2013-07, Vol.11 (4), p.363-370

2013

Volltextzugriff (PDF)

Interim analysis incorporating short‐ and long‐term binary endpoints

Biometrical journal, 2019-05, Vol.61 (3), p.665-687

2019

Volltextzugriff (PDF)

Confidence regions for treatment effects in subgroups in biomarker stratified designs

Biometrical journal, 2019-01, Vol.61 (1), p.27-39

2019

Volltextzugriff (PDF)

Curtailment in single-arm two-stage phase II oncology trials

Biometrical journal, 2012-07, Vol.54 (4), p.445-456

2012

Volltextzugriff (PDF)

Simon's Minimax and Optimal and Jung's Admissible Two-stage Designs with or without Curtailment

The Stata journal, 2011-07, Vol.11 (2), p.240-254

2011

Volltextzugriff (PDF)

Measuring organizational attributes in primary care: a validation study in Germany

Journal of evaluation in clinical practice, 2010-12, Vol.16 (6), p.1289-1294

2010

Volltextzugriff (PDF)

Das ABC der medizinischen Statistik

Der junge Zahnarzt, 2010-12, Vol.1 (4), p.12-13

2010

Volltextzugriff (PDF)

Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation

Haematologica (Roma), 2015-11, Vol.100 (11), p.1442-1450

2015

Volltextzugriff (PDF)

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial

Lancet neurology, 2019-08, Vol.18 (8), p.724-735

2019

Volltextzugriff (PDF)

Chromatin accessibility landscape of pediatric T‐lymphoblastic leukemia and human T‐cell precursors

EMBO molecular medicine, 2020-09, Vol.12 (9), p.e12104-n/a

2020

Volltextzugriff (PDF)

The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis

Journal of neurology, 2024-05, Vol.271 (5), p.2639-2648

2024

Volltextzugriff (PDF)

NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia

Haematologica (Roma), 2017-07, Vol.102 (7), p.e249-e252

2017

Volltextzugriff (PDF)

TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL)

Blood, 2021-11, Vol.138 (Supplement 1), p.1315-1315

2021

Volltextzugriff (PDF)

Identification of an Ultra High-Risk and Targetable Molecular Signature in Relapsed Pediatric T-ALL

Blood, 2016-12, Vol.128 (22), p.1084-1084

2016

Volltextzugriff (PDF)

Gene Panel Sequencing of Primary and Relapsed Pediatric T-ALL Shows That Relapse-Specific Mutations Are Diverse and Mostly Non-Recurrent

Blood, 2015-12, Vol.126 (23), p.1428-1428

2015

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(29)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(20)
Humans
(14)
Female
(7)
Male
(7)
Mathematics
(7)
Physical Sciences
(7)
Statistics & Probability
(7)
Clinical Trials
(6)
Mathematical & Computational Biology
(6)
Health Care Sciences & Services
(5)
Middle Aged
(5)
Aged
(4)
Conditional Power
(4)
Germany
(4)
Hematology
(4)
Medical Informatics
(4)
Mutation
(4)
Patients
(4)
Time Factors
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Two-stage phase II oncology designs using short-term endpoints for early stopping

Case management for patients with chronic systolic heart failure in primary care: the HICMan exploratory randomised controlled trial

Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations

Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints

Patient- and provider-related determinants of generic and specific health-related quality of life of patients with chronic systolic heart failure in primary care: a cross-sectional study

Strategies for Reducing Potentially Avoidable Hospitalizations for Ambulatory Care–Sensitive Conditions

Interim analysis incorporating short‐ and long‐term binary endpoints

Confidence regions for treatment effects in subgroups in biomarker stratified designs

Curtailment in single-arm two-stage phase II oncology trials

Simon's Minimax and Optimal and Jung's Admissible Two-stage Designs with or without Curtailment

Measuring organizational attributes in primary care: a validation study in Germany

Das ABC der medizinischen Statistik

Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial

PDX models recapitulate the genetic and epigenetic landscape of pediatric T‐cell leukemia

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

Chromatin accessibility landscape of pediatric T‐lymphoblastic leukemia and human T‐cell precursors

Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution

The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis

NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia

TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL)

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Identification of an Ultra High-Risk and Targetable Molecular Signature in Relapsed Pediatric T-ALL

Gene Panel Sequencing of Primary and Relapsed Pediatric T-ALL Shows That Relapse-Specific Mutations Are Diverse and Mostly Non-Recurrent

Suchergebnisse filtern